연구동향 분석

Synthesis and Biological Evaluation of Nature-inspired Cudraisoflavone Analogues as Potential Neuroprotective Agents

륙계려 2022년

논문상세정보
인용/피인용
' Synthesis and Biological Evaluation of Nature-inspired Cudraisoflavone Analogues as Potential Neuroprotective Agents' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 약리학과 치료학
  • cudraisoflavone
  • parkinson's disease
  • total synthesis
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
882 0

0.0%

' Synthesis and Biological Evaluation of Nature-inspired Cudraisoflavone Analogues as Potential Neuroprotective Agents' 의 참고문헌

  • Ubiquitination of alpha-synuclein and autophagy in parkinson 's disease
    Engelender , S. 4 ( 3 ) , 372-374 . [2008]
  • The rs3756063 polymorphism is associated with snca methylation in the chinese han population
    Wei , Y. , et al. 367 , 11-14 . [2016]
  • Role of oxidative stress in parkinson 's disease
    Hwang , O. 22 ( 1 ) , 11-17 . [2013]
  • Resveratrol protects pc12 cell against 6-ohda damage via cxcr4 signaling pathway
  • Neurotoxicant-induced animal models of parkinson 's disease : Understanding the role of rotenone , maneb and paraquat in neurodegeneration
    Uversky , V. N. , 318 ( 1 ) , 225-241 . [2004]
  • Identification of motor and nonmotor wearing-off in parkinson 's disease : Comparison of a patient questionnaire versus a clinician assessment
    Stacy , M. , et al. 20 ( 6 ) , 726-733 . [2005]
  • Genetics of parkinson 's disease
    Lill , C. M. , 30 ( 6 ) , 386-396 . [2016]
  • Classic toxin-induced animal models of parkinson 's disease : 6-ohda and mptp
    Schober , A. 318 ( 1 ) , 215-224 . [2004]
  • Alzheimer 's disease drug development and the problem of the blood-brain barrier
    Pardridge , W. M. 5 ( 5 ) , 427-432 . [2009]
  • 94. Do, H. T. T.; Bui, B. P.; Sim, S.; Jung, J. K.; Lee, H..Cho, J., Anti-inflammatory and anti-migratory activities of isoquinoline-1-carboxamide derivatives in lps-treated bv2 microglial cells via inhibition of mapks/nf-kappab pathway. Int J Mol Sci 2020, 21 (7).
    [2020]
  • 93. Buratta, S., et al., Effect of curcumin on protein damage induced by rotenone in dopaminergic pc12 cells. Int J Mol Sci 2020, 21 (8).
    [2020]
  • 92. Gupta, S.; Biswas, J.; Gupta, P.; Singh, A.; Tiwari, S.; Mishra, A..Singh, S., Salubrinal attenuates nitric oxide mediated perk:Ire1alpha: Atf-6 signaling and DNA damage in neuronal cells. Neurochem Int 2019, 131, 104581.
    [2019]
  • 91. Zhang, L. J., et al., Human albumin prevents 6- hydroxydopamine-induced loss of tyrosine hydroxylase in in vitro and in vivo. PLoS One 2012, 7 (7), e41226.
    [2012]
  • 90. Ma, Y.; Liu, Y.; Sun, A.; Du, Y.; Ye, M.; Pu, X..Qi, X., Intestinal absorption and neuroprotective effects of kaempferol-3-o-rutinoside. RSC Advances 2017, 7 (50), 31408-31416.
    [2017]
  • 9. Dauer, W..Przedborski, S., Parkinson's disease: Mechanisms and models. Neuron 2003, 39 (6), 889-909.
    [2003]
  • 88. Kim, Y.; Li, E..Park, S., Insulin-like growth factor-1 inhibits 6-hydroxydopamine-mediated endoplasmic reticulum stressinduced apoptosis via regulation of heme oxygenase-1 and nrf2 expression in pc12 cells. Int J Neurosci 2012, 122 (11), 641-649.
    [2012]
  • 87. Wang, Z.; Wu, J.; Yang, X.; Cai, P.; Liu, Q.; Wang, K. D. G.; Kong, L..Wang, X., Neuroprotective effects of benzyloxy substituted small molecule monoamine oxidase b inhibitors in parkinson's disease. Bioorg Med Chem 2016, 24 (22), 5929- 5940.
    [2016]
  • 86. Hu, R.; Cao, Q.; Sun, Z.; Chen, J.; Zheng, Q..Xiao, F., A novel method of neural differentiation of pc12 cells by using opti-mem as a basic induction medium. Int J Mol Med 2018, 41 (1), 195-201.
    [2018]
  • 84. Daina, A..Zoete, V., Application of the swissdrugdesign online resources in virtual screening. Int J Mol Sci 2019, 20 (18).
    [2019]
  • 83. van de Waterbeemd, H..Gifford, E., Admet in silico modelling: Towards prediction paradise? Nat Rev Drug Discov 2003, 2 (3), 192-204.
    [2003]
  • 82. Betarbet, R.; Sherer, T. B.; MacKenzie, G.; Garcia-Osuna, M.; Panov, A. V..Greenamyre, J. T., Chronic systemic pesticide exposure reproduces features of parkinson's disease. Nature Neuroscience 2000, 3 (12), 1301-1306.
    [2000]
  • 80. Wiatrak, B.; Kubis-Kubiak, A.; Piwowar, A..Barg, E., Pc12 cell line: Cell types, coating of culture vessels, differentiation and other culture conditions. Cells 2020, 9 (4).
    [2020]
  • 8. Oertel, W..Schulz, J. B., Current and experimental treatments of parkinson disease: A guide for neuroscientists. J Neurochem 2016, 139 Suppl 1, 325-337.
    [2016]
  • 79. Matsuzaki, Y., et al., Sustained neurotrophin release from protein nanoparticles mediated by matrix metalloproteinases induces the alignment and differentiation of nerve cells. Biomolecules 2019, 9 (10).
    [2019]
  • 78. de Los Rios, C.; Cano-Abad, M. F.; Villarroya, M..Lopez, M. G., Chromaffin cells as a model to evaluate mechanisms of cell death and neuroprotective compounds. Pflugers Arch 2018, 470 (1), 187-198.
    [2018]
  • 77. Westerink, R. H..Ewing, A. G., The pc12 cell as model for neurosecretion. Acta Physiol (Oxf) 2008, 192 (2), 273-285.
    [2008]
  • 76. Wang, W.-L.; Dai, R.; Yan, H.-W.; Han, C.-N.; Liu, L.- S..Duan, X.-H., Current situation of pc12 cell use in neuronal injury study. International Journal of Biotechnology for Wellness Industries 2015, 4 (2), 61-66.
    [2015]
  • 75. Ateba, S. B.; Mvondo, M. A.; Djiogue, S.; Zingue, S.; Krenn, L..Njamen, D., A pharmacological overview of alpinumisoflavone, a natural prenylated isoflavonoid. Front Pharmacol 2019, 10, 952.
    [2019]
  • 74. Han, X. H., et al., Monoamine oxidase inhibitory constituents from the fruits of cudrania tricuspidata. Archives of pharmacal research 2005, 28 (12), 1324-1327.
    [2005]
  • 73. Sivaraman, A.; Harmalkar, D. S.; Kang, J.; Choi, Y..Lee, K., A protecting group-free divergent synthesis of natural benzofurans via one-pot synthesis of 2-bromo-6- hydroxybenzofurans. Org Biomol Chem 2019, 17 (8), 2153- 2161.
    [2019]
  • 72. Harmalkar, D. S.; Lu, Q..Lee, K., Total synthesis of gramistilbenoids a, b, and c. J Nat Prod 2018, 81 (4), 798-805.
    [2018]
  • 71. Li, Y.; Luo, Y.; Huang, W.; Wang, J..Lu, W., Total synthesis of mallotophilippen c. Tetrahedron Letters 2006, 47 (25), 4153-4155.
    [2006]
  • 70. Lu, Q.; Harmalkar, D. S.; Quan, G.; Kwon, H.; Cho, J.; Choi, Y.; Lee, D..Lee, K., Total synthesis of the neuroprotective agent cudraisoflavone j. J Nat Prod 2021, 84 (4), 1359-1365.
  • 7. Kalia, L. V..Lang, A. E., Parkinson's disease. The Lancet 2015, 386 (9996), 896-912.
    [2015]
  • 69. Stacy, M.; Hauser, R.; Oertel, W.; Schapira, A.; Sethi, K.; Stocchi, F..Tolosa, E., End-of-dose wearing off in parkinson disease: A 9-question survey assessment. Clin Neuropharmacol 2006, 29 (6), 312-321.
    [2006]
  • 67. A controlled, randomized, delayed-start study of rasagiline in early parkinson disease. Arch Neurol 2004, 61 (4), 561-566.
    [2004]
  • 66. AlDakheel, A.; Kalia, L. V..Lang, A. E., Pathogenesistargeted, disease-modifying therapies in parkinson disease. Neurotherapeutics 2014, 11 (1), 6-23.
    [2014]
  • 65. Tran, H. T.; Chung, C. H.; Iba, M.; Zhang, B.; Trojanowski, J. Q.; Luk, K. C..Lee, V. M., Alpha-synuclein immunotherapy blocks uptake and templated propagation of misfolded alphasynuclein and neurodegeneration. Cell Rep 2014, 7 (6), 2054- 2065.
    [2014]
  • 64. Circu, M. L..Aw, T. Y., Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med 2010, 48 (6), 749-762.
    [2010]
  • 63. Bisbal, M..Sanchez, M., Neurotoxicity of the pesticide rotenone on neuronal polarization: A mechanistic approach. Neural Regen Res 2019, 14 (5), 762-766.
    [2019]
  • 62. Inden, M., et al., Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone. J Neurochem 2007, 101 (6), 1491-1504.
    [2007]
  • 61. Manning-Bog, A. B.; McCormack, A. L.; Li, J.; Uversky, V. N.; Fink, A. L..Di Monte, D. A., The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: Paraquat and alpha-synuclein. J Biol Chem 2002, 277 (3), 1641-1644.
    [2002]
  • 60. Wang, Q.; Zhan, Y.; Ren, N.; Wang, Z.; Zhang, Q.; Wu, S..Li, H., Paraquat and mptp alter microrna expression profiles, and downregulated expression of mir-17-5p contributes to pq-induced dopaminergic neurodegeneration. J Appl Toxicol 2018, 38 (5), 665-677.
    [2018]
  • 6. Schneider, R. B.; Iourinets, J..Richard, I. H., Parkinson's disease psychosis: Presentation, diagnosis and management. Neurodegener Dis Manag 2017, 7 (6), 365-376.
    [2017]
  • 59. Shimizu, K., et al., Carrier-mediated processes in blood-- brain barrier penetration and neural uptake of paraquat. Brain Res 2001, 906 (1-2), 135-142.
    [2001]
  • 57. Burke, W. J., et al., Aggregation of alpha-synuclein by dopal, the monoamine oxidase metabolite of dopamine. Acta Neuropathol 2008, 115 (2), 193-203.
    [2008]
  • 56. Nonnekes, J.; Post, B.; Tetrud, J. W.; Langston, J. W..Bloem, B. R., Mptp-induced parkinsonism: An historical case series. The Lancet Neurology 2018, 17 (4), 300-301.
    [2018]
  • 55. Vareslija, D.; Tipton, K. F.; Davey, G. P..McDonald, A. G., 6-hydroxydopamine: A far from simple neurotoxin. J Neural Transm (Vienna) 2020, 127 (2), 213-230.
    [2020]
  • 53. Haleagrahara, N.; Siew, C. J..Ponnusamy, K., Effect of quercetin and desferrioxamine on 6-hydroxydopamine (6- ohda) induced neurotoxicity in striatum of rats. J Toxicol Sci 2013, 38 (1), 25-33.
    [2013]
  • 52. Perese, D. A.; Ulman, J.; Viola, J.; Ewing, S. E..Bankiewicz, K. S., A 6-hydroxydopamine-induced selective parkinsonian rat model. Brain Research 1989, 494 (2), 285-293.
    [1989]
  • 51. Simola, N.; Morelli, M..Carta, A. R., The 6-hydroxydopamine model of parkinson's disease. Neurotox Res 2007, 11 (3-4), 151-167.
    [2007]
  • 50. Chia, S. J.; Tan, E. K..Chao, Y. X., Historical perspective: Models of parkinson's disease. Int J Mol Sci 2020, 21 (7).
    [2020]
  • 5. Bellou, V.; Belbasis, L.; Tzoulaki, I.; Evangelou, E..Ioannidis, J. P., Environmental risk factors and parkinson's disease: An umbrella review of meta-analyses. Parkinsonism Relat Disord 2016, 23, 1-9.
    [2016]
  • 49. Salari, S..Bagheri, M., In vivo, in vitro and pharmacologic models of parkinson's disease. Physiol Res 2019, 68 (1), 17- 24.
    [2019]
  • 48. Blesa, J.; Phani, S.; Jackson-Lewis, V..Przedborski, S., Classic and new animal models of parkinson's disease. J Biomed Biotechnol 2012, 2012, 845618.
    [2012]
  • 47. Falkenburger, B. H.; Saridaki, T..Dinter, E., Cellular models for parkinson's disease. J Neurochem 2016, 139 Suppl 1, 121- 130.
    [2016]
  • 46. Dickson, D. W., et al., Neuropathological assessment of parkinson's disease: Refining the diagnostic criteria. The Lancet Neurology 2009, 8 (12), 1150-1157.
    [2009]
  • 45. Eriksen, J. L.; Przedborski, S..Petrucelli, L., Gene dosage and pathogenesis of parkinson's disease. Trends Mol Med 2005, 11 (3), 91-96.
    [2005]
  • 42. Singleton, A. B.; Farrer, M. J..Bonifati, V., The genetics of parkinson's disease: Progress and therapeutic implications. Mov Disord 2013, 28 (1), 14-23.
    [2013]
  • 41. Hurtig, H., et al., Alpha-synuclein cortical lewy bodies correlate with dementia in parkinson’s disease. Neurology 2000, 54 (10), 1916-1921.
    [2000]
  • 40. Polymeropoulos, M. H., et al., Mutation in the α-synuclein gene identified in families with parkinson's disease. science 1997, 276 (5321), 2045-2047.
    [1997]
  • 4. Corti, O.; Lesage, S..Brice, A., What genetics tells us about the causes and mechanisms of parkinson's disease. Physiol Rev 2011, 91 (4), 1161-1218.
    [2011]
  • 39. Masters, C. L.; Kril, J. J.; Halliday, G. M.; Pamphlett, R.; Collins, S.; Hill, A. F..McLean, C., Overview and recent advances in neuropathology. Part 2: Neurodegeneration. Pathology 2011, 43 (2), 93-102.
    [2011]
  • 38. Giguere, N.; Burke Nanni, S..Trudeau, L. E., On cell loss and selective vulnerability of neuronal populations in parkinson's disease. Front Neurol 2018, 9, 455.
    [2018]
  • 37. Rudow, G., et al., Morphometry of the human substantia nigra in ageing and parkinson's disease. Acta Neuropathol 2008, 115 (4), 461-470.
    [2008]
  • 36. Kordower, J. H.; Olanow, C. W.; Dodiya, H. B.; Chu, Y.; Beach, T. G.; Adler, C. H.; Halliday, G. M..Bartus, R. T., Disease duration and the integrity of the nigrostriatal system in parkinson's disease. Brain 2013, 136 (Pt 8), 2419-2431.
    [2013]
  • 35. Armstrong, M. J..Okun, M. S., Diagnosis and treatment of parkinson disease: A review. JAMA 2020, 323 (6), 548-560.
    [2020]
  • 34. Kouli, A.; Torsney, K. M..Kuan, W. L., Parkinson's disease: Etiology, neuropathology, and pathogenesis. In Parkinson's disease: Pathogenesis and clinical aspects, Stoker, T. B..Greenland, J. C., Eds. Brisbane (AU), 2018.
    [2018]
  • 33. Biosa, A.; Sanchez-Martinez, A.; Filograna, R.; Terriente- Felix, A.; Alam, S. M.; Beltramini, M.; Bubacco, L.; Bisaglia, M..Whitworth, A. J., Superoxide dismutating molecules rescue the toxic effects of pink1 and parkin loss. Hum Mol Genet 2018, 27 (9), 1618-1629.
    [2018]
  • 32. Montaut, S., et al., Assessment of a targeted gene panel for identification of genes associated with movement disorders. JAMA Neurol 2018, 75 (10), 1234-1245.
    [2018]
  • 31. Shu, L.; Zhang, Y.; Sun, Q.; Pan, H.; Guo, J..Tang, B., Snca rep1 and parkinson's disease. Neurosci Lett 2018, 682, 79-84.
    [2018]
  • 30. Blauwendraat, C.; Nalls, M. A..Singleton, A. B., The genetic architecture of parkinson's disease. The Lancet Neurology 2020, 19 (2), 170-178.
    [2020]
  • 3. Dorsey, E. R., et al., Global, regional, and national burden of parkinson's disease, 1990–2016: A systematic analysis for the global burden of disease study 2016. The Lancet Neurology 2018, 17 (11), 939-953.
    [2018]
  • 29. Gilks, W. P., et al., A common lrrk2 mutation in idiopathic parkinson's disease. The Lancet 2005, 365 (9457), 415-416.
    [2005]
  • 27. Savica, R.; Cannon-Albright, L. A..Pulst, S., Familial aggregation of parkinson disease in utah: A population-based analysis using death certificates. Neurol Genet 2016, 2 (2), e65.
    [2016]
  • 26. Ullah, I.; Zhao, L.; Hai, Y.; Fahim, M.; Alwayli, D.; Wang, X..Li, H., "Metal elements and pesticides as risk factors for parkinson's disease - a review". Toxicol Rep 2021, 8, 607- 616.
  • 25. Nandipati, S..Litvan, I., Environmental exposures and parkinson's disease. Int J Environ Res Public Health 2016, 13 (9).
    [2016]
  • 24. de Lau, L. M. L..Breteler, M. M. B., Epidemiology of parkinson's disease. The Lancet Neurology 2006, 5 (6), 525- 535.
    [2006]
  • 23. Mustapha, M..Mat Taib, C. N., Mptp-induced mouse model of parkinson's disease: A promising direction of therapeutic strategies. Bosn J Basic Med Sci 2021, 21 (4), 422-433.
  • 22. Langston, J. W., Mptp and parkinson's disease. Trends in Neurosciences 1985, 8, 79-83.
    [1985]
  • 21. Blum, D.; Torch, S.; Lambeng, N.; Nissou, M.; Benabid, A. L.; Sadoul, R..Verna, J. M., Molecular pathways involved in the neurotoxicity of 6-ohda, dopamine and mptp: Contribution to the apoptotic theory in parkinson's disease. Prog Neurobiol 2001, 65 (2), 135-172.
    [2001]
  • 20. Gao, H. M..Hong, J. S., Gene-environment interactions: Key to unraveling the mystery of parkinson's disease. Prog Neurobiol 2011, 94 (1), 1-19.
    [2011]
  • 2. Dorsey, E. R..Bloem, B. R., The parkinson pandemic-a call to action. JAMA Neurol 2018, 75 (1), 9-10.
    [2018]
  • 19. Ghatak, S.; Trudler, D.; Dolatabadi, N..Ambasudhan, R., Parkinson’s disease: What the model systems have taught us so far. Journal of Genetics 2018, 97 (3), 729-751.
    [2018]
  • 18. Ascherio, A..Schwarzschild, M. A., The epidemiology of parkinson's disease: Risk factors and prevention. The Lancet Neurology 2016, 15 (12), 1257-1272.
    [2016]
  • 17. Simon, D. K.; Tanner, C. M..Brundin, P., Parkinson disease epidemiology, pathology, genetics, and pathophysiology. Clin Geriatr Med 2020, 36 (1), 1-12.
    [2020]
  • 16. Tysnes, O. B..Storstein, A., Epidemiology of parkinson's disease. J Neural Transm (Vienna) 2017, 124 (8), 901-905.
    [2017]
  • 15. Chaudhuri, K. R..Schapira, A. H., Non-motor symptoms of parkinson's disease: Dopaminergic pathophysiology and treatment. Lancet Neurol 2009, 8 (5), 464-474.
    [2009]
  • 14. Khoo, T. K.; Yarnall, A. J.; Duncan, G. W.; Coleman, S.; O'Brien, J. T.; Brooks, D. J.; Barker, R. A..Burn, D. J., The spectrum of nonmotor symptoms in early parkinson disease. Neurology 2013, 80 (3), 276-281.
    [2013]
  • 13. Kumaresan, M..Khan, S., Spectrum of non-motor symptoms in parkinson's disease. Cureus 2021, 13 (2), e13275.
  • 12. Meredith, G. E..Kang, U. J., Behavioral models of parkinson's disease in rodents: A new look at an old problem. Mov Disord 2006, 21 (10), 1595-1606.
    [2006]
  • 11. Titova, N.; Padmakumar, C.; Lewis, S. J. G..Chaudhuri, K. R., Parkinson's: A syndrome rather than a disease? J Neural Transm (Vienna) 2017, 124 (8), 907-914.
    [2017]
  • 10. Opara, J.; Malecki, A.; Malecka, E..Socha, T., Motor assessment in parkinson`s disease. Ann Agric Environ Med 2017, 24 (3), 411-415.
    [2017]
  • 1. Sveinbjornsdottir, S., The clinical symptoms of parkinson's disease. J Neurochem 2016, 139 Suppl 1, 318-324.
    [2016]